|Bid||61.06 x 900|
|Ask||61.72 x 800|
|Day's Range||61.26 - 62.70|
|52 Week Range||45.76 - 67.16|
|Beta (5Y Monthly)||0.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||1.96 (3.20%)|
|Ex-Dividend Date||Dec 31, 2020|
|1y Target Est||75.13|
Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year. Shares down.
Bristol Myers Squibb topped fourth-quarter expectations in February and cancer drug Opdivo returned to growth. But BMY stock floundered following the report. Is Bristol Myers stock a buy?
BMS Receives Positive CHMP Opinion for Opdivo® in Combination with Cabometyx® as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma